What are the specific adverse reactions of filgotinib?

Filgotinib (Filgotinib), as a selective JAK1 inhibitor, exerts an inhibitory effect on the inflammatory signaling pathway, and may also be associated with certain adverse reactions. As drugs for the long-term management of rheumatoid arthritis and ulcerative colitis, understanding their possible side effects is important for rational monitoring and safe use. Although there are individual differences in drug tolerance among different patients, relatively common reaction manifestations are still summarized in overseas drug data.

One of the more typical adverse reactions is an increased risk of infection, which is becauseThe JAK pathway is a key link in the human immune response. When drugs inhibit inflammatory signals, they also reduce the response ability of certain immune cells, making upper respiratory tract infections, pharyngitis, bronchitis and other mild infections more likely to occur. However, most of them are within the controllable range, and you only need to seek medical treatment in time when symptoms such as fever and cough appear. Doctors often evaluate patients for past infections or potential latent infections before prescribing the drug to reduce risk.

In addition, some patients may experience gastrointestinal discomfort, such as diarrhea, nausea or mild abdominal pain, which is related to changes in the intestinal environment after immune regulation. Most of them appear in the early stages of treatment and gradually resolve. If symptoms persist, you should discuss with your doctor to adjust dosage or treatment strategy. Fatigue and headache are also common systemic reactions. These symptoms are usually mild and can be improved with proper rest.

In terms of laboratory tests, some patients may have mild elevations in liver enzymes or changes in blood indicators, such as leukopenia or changes in blood lipids. Since these reactions often have no obvious clinical symptoms, doctors usually conduct liver function tests and routine blood tests regularly during the initial period of drug use and during treatment to ensure safety.

Reference materials:https://go.drugbank.com/drugs/DB14845